Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer - GlobeNewswire
5/11/2022 12:00:00 AM2 years 11 months ago
by Lantheus Holdings, Inc.
by Lantheus Holdings, Inc.
PYLARIFY® (piflufolastat F18) injection was the first commercially available PSMA-targeted PET imaging agent for prostate cancer......
NORTH BILLERICA, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diag… [+11925 chars]
full article...